SEC Form 4 · accession 0001104659-19-003144
RHYTHM PHARMACEUTICALS, INC. · RYTM
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Keith Michael Gottesdiener
Officer — CEO and President · Director
Period of report
Jan 22, 2019
Accepted (ET)
Jan 24, 2019 · 4:03 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001649904
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF2 | Jan 22, 2019 | S | 15,674 | $30.05 | D | 545,025 | D | |
| Common Stock | Jan 23, 2019 | S | 105 | $30.21 | D | 544,920 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1On January 22, 2019, Mr. Gottesdiener sold 15,674 shares pursuant to a plan of disposition adopted in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended.
- F2This transaction was executed in multiple trades at prices ranging from $30.00 to $30.63, inclusive; the price reported above reflects the weighted average sale price. Mr. Gottesdiener hereby undertakes to provide to the Securities and Exchange Commission staff, the issuer or any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected.
- F3On January 23, 2019, Mr. Gottesdiener sold 105 shares pursuant to a plan of disposition adopted in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended.